Substance / Medication

Abacavir

Overview

Active Ingredient
abacavir
RxNorm CUI
190521

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Safety and efficacy of abacavir for treating infants, children, and adolescents living with HIV: a systematic review and meta-analysis.
Jesson Julie, Saint-Lary Laura, Revegue Marc Harris Dassi Tchoupa et al. · Lancet Child Adolesc Health · 2022
PMID: 36058225Meta-AnalysisFull text (PMC)
Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure.
Stainsby Chris M, Perger Teodora M, Vannappagari Vani et al. · Pharmacotherapy · 2019
PMID: 30414209Meta-AnalysisFull text (PMC)
Adverse events associated with abacavir use in HIV-infected children and adolescents: a systematic review and meta-analysis.
Jesson Julie, Dahourou Désiré L, Renaud Françoise et al. · Lancet HIV · 2016
PMID: 26847228Meta-Analysis
Pharmacogenetics of abacavir hypersensitivity: A systematic review and meta-analysis of the association with HLA-B*57:01.
Sousa-Pinto Bernardo, Pinto-Ramos João, Correia Cláudia et al. · J Allergy Clin Immunol · 2015
PMID: 25934581Meta-Analysis
Association of HLA-B*5701 genotypes and abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis.
Tangamornsuksan Wimonchat, Lohitnavy Ornrat, Kongkaew Chuenjid et al. · J Pharm Pharm Sci · 2015
PMID: 25877443Meta-Analysis
Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.
Lehmann David S, Ribaudo Heather J, Daar Eric S et al. · Pharmacogenet Genomics · 2015
PMID: 25461247Meta-AnalysisFull text (PMC)
Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review.
Cargnin Sarah, Jommi Claudio, Canonico Pier Luigi et al. · Pharmacogenomics · 2014
PMID: 24956250Meta-Analysis
Virological efficacy of abacavir: systematic review and meta-analysis.
Cruciani Mario, Mengoli Carlo, Malena Marina et al. · J Antimicrob Chemother · 2014
PMID: 25074854Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Abacavir (substance)
SNOMED CT
387005008
UMLS CUI
C0663655
RxNorm CUI
190521

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.